MSInsight

H24

Description

MSInsight is a precision oncology company developing advanced genomic diagnostic tools to improve cancer detection and treatment decision-making. Specializing in microsatellite instability (MSI) and DNA repair biomarkers, MSInsight combines next-generation sequencing with proprietary algorithmic approaches to deliver clear, clinically actionable insights from complex genomic data. Our flagship software, MSIcare, supports laboratories and clinicians in detecting MSI and characterizing tumor genomic instability across solid cancers. MSInsight is also developing Gemini, a novel sequencing-based diagnostic algorithm enabling early detection of Constitutional Mismatch Repair Deficiency (CMMRD), a severe pediatric cancer predisposition syndrome. Rooted in strong collaborations with leading French and international research centers, MSInsight aims to make high-quality biomarker diagnostics more accessible, interoperable, and deployable across real-world clinical environments. Mission: Unlock the full potential of genomic biomarkers to advance precision oncology and improve patient outcomes.